RVNC Revance Therapeutics Inc.

16.37
+1.22  (+8%)
Previous Close 15.15
Open 15.73
Price To Book 4.14
Market Cap 933,583,605
Shares 57,030,153
Volume 503,058
Short Ratio
Av. Daily Volume 1,021,832
Stock charts supplied by TradingView

NewsSee all news

  1. Revance to Participate in the 19th Annual Needham Virtual Healthcare Conference

  2. Revance Provides Corporate Update in Light of COVID-19

    Key Changes to 2020 Plan: - Launch of RHA® fillers, and associated hiring of 100 field representatives, pushed back one quarter due to COVID-19 situation and temporary closure of Teoxane's Swiss manufacturing facility

  3. Revance to Participate in the Barclays Global Healthcare Conference 2020

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection

  4. Revance to Participate in the Cowen 40th Annual Health Care Conference

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection

  5. Revance Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update

    - Conference call and webcast today at 4:30 p.m. ET - Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data due 2H 2020.
DAXI (RT002)
Plantar fasciitis
Phase 2 top-line data due 2Q 2020.
DAXI (RT002)
Lateral Canthal (Crow’s Feet) Lines
Phase 3 data due 2H 2020.
DAXI (RT002) - ASPEN
Cervical dystonia
PDUFA date November 25, 2020.
DAXI (RT002)
Moderate to severe glabellar (frown) lines
Phase 2 trial to be initiated in 2020.
DAXI (RT002)
Chronic migraine
Phase 2 enrolment has been paused due to COVID-19.
DAXI (RT002)
Upper limb spasticity
Phase 2 top-line data due 2Q 2020.
DAXI (RT002)
Forehead lines
Phase 2 data due 4Q 2020. Timeline update due later depending on COVID-19.
DAXI (RT002)
Full Upper Face

Latest News

  1. Revance to Participate in the 19th Annual Needham Virtual Healthcare Conference

  2. Revance Provides Corporate Update in Light of COVID-19

    Key Changes to 2020 Plan: - Launch of RHA® fillers, and associated hiring of 100 field representatives, pushed back one quarter due to COVID-19 situation and temporary closure of Teoxane's Swiss manufacturing facility

  3. Revance to Participate in the Barclays Global Healthcare Conference 2020

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection

  4. Revance to Participate in the Cowen 40th Annual Health Care Conference

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection

  5. Revance Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update

    - Conference call and webcast today at 4:30 p.m. ET - Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation

  6. Revance to Release Fourth Quarter and Full Year 2019 Financial Results on Monday, February 24, 2020

    Conference Call Scheduled for Monday, February 24, 2020 at 4:30 p.m. ET Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its

  7. Revance Announces Pricing of $250 Million of Convertible Senior Notes Due 2027

    Revance Therapeutics, Inc. ("Revance") (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the pricing of $250.0

  8. Revance Announces Proposed Private Offering of $200 Million of Convertible Senior Notes Due 2027

      Revance Therapeutics, Inc. ("Revance") (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that it intends to

  9. Revance Announces U.S. FDA Acceptance of Biologics License Application (BLA) for DAXI to Treat Glabellar (Frown) Lines

    - Prescription Drug User Fee Act (PDUFA) target action date of November 25, 2020 - Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including

  10. Revance Announces Transformative Aesthetics Portfolio Transaction with Exclusive U.S. Distribution Agreement of FDA-Approved Dermal Fillers from TEOXANE SA

    - TEOXANE SA RHA® portfolio: first and only range of FDA-approved dermal fillers for correction of dynamic wrinkles - - Revance gains access to the growing $1.1B U.S. filler market with three differentiated products,

  11. Revance to Participate in the 38th Annual J.P. Morgan Healthcare Conference

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, today announced that the company will participate in the

  12. Revance Provides Corporate Update and Anticipated Milestones for 2020

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, today provided a corporate and product pipeline update

  13. Revance Announces Publication of Pooled Results from Phase 3 Trials for Glabellar Lines in the Journal of the American Academy of Dermatology

    DaxibotulinumtoxinA for Injection (DAXI) demonstrated prolonged duration of response for glabellar line reduction Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in

  14. Revance Announces Pricing of Public Offering of Common Stock

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced the

  15. Revance Announces Proposed Public Offering of Common Stock

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced a

  16. Revance Promotes Dustin Sjuts to Chief Commercial Officer, Aesthetics & Therapeutics

    - Appointment completes build-out of Revance's commercial leadership team following submission of the Company's Biologics License Application to the U.S. Food and Drug Administration for DaxibotulinumtoxinA for

  17. Revance Submits Biologics License Application (BLA) to the FDA for DAXI to Treat Glabellar (Frown) Lines

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, today announced the Company has submitted a Biologics

  18. Revance to Participate in the Stifel 2019 Healthcare Conference

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Stifel

  19. Revance Reports Third Quarter 2019 Financial Results, Provides Corporate Update

    – Conference call and webcast today at 4:30 p.m. ET – Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today

  20. Revance Completes Enrollment in ASPEN-1 Phase 3 Pivotal Trial for Cervical Dystonia

    - DaxibotulinumtoxinA for Injection (DAXI) has potential to be first long-acting neuromodulator for treatment of this debilitating involuntary muscle movement disorder - - Topline data expected in second half of 2020

  21. Revance Announces Publication of SAKURA 1 and SAKURA 2 Results in Plastic and Reconstructive Surgery

    - Results show DaxibotulinumtoxinA for Injection (DAXI) can reduce frown lines for 24 weeks (approximately 6 months) or more - Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new

  22. Revance to Release Third Quarter 2019 Financial Results on Monday, November 4, 2019

    Conference Call Scheduled for Monday, November 4, 2019 at 4:30 p.m. ET Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic

  23. Revance Appoints Mark J. Foley as President and CEO, Replacing Dan Browne

    - Mark Foley to lead company as it gears up to commercialize next-generation neuromodulator – - Change in leadership unrelated to company performance - - Revance on track to submit BLA for DAXI for the treatment of

  24. Revance Earns Great Place to Work® Certification for Second Year

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced the company is certified as a great workplace by

  25. Revance to Participate in the 2019 Cantor Global Healthcare Conference

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the 2019

  26. Revance to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Morgan

  27. Revance to Participate in the Wells Fargo 14th Annual Healthcare Conference

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Wells